{"id":60058,"date":"2026-03-19T23:24:49","date_gmt":"2026-03-19T15:24:49","guid":{"rendered":"https:\/\/flcube.com\/?p=60058"},"modified":"2026-03-19T23:24:51","modified_gmt":"2026-03-19T15:24:51","slug":"konruns-pharma-wins-nmpa-phase-iii-approval-for-kc1036-multi-target-vegfr2-axl-inhibitor-targets-thymic-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60058","title":{"rendered":"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\/AXL Inhibitor Targets Thymic Carcinoma"},"content":{"rendered":"\n<p><strong>Konruns Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603590:SHA\">SHA: 603590<\/a>) received <strong>National Medical Products Administration (NMPA) approval<\/strong> to initiate a <strong>Phase III clinical study<\/strong> for <strong>KC1036<\/strong>, a <strong>Category 1 innovative chemical drug<\/strong>. The study targets <strong>advanced recurrent or metastatic thymic carcinoma<\/strong> in patients who have <strong>failed at least one prior line of platinum-based chemotherapy<\/strong>, positioning KC1036 as a potential <strong>first-in-class therapy<\/strong> for this ultra-rare, aggressive malignancy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Phase III clinical trial authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>KC1036 (Category 1 chemical drug)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Konruns Pharmaceutical Co., Ltd. (SHA: 603590)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced recurrent or metastatic thymic carcinoma (post-platinum failure)<\/td><\/tr><tr><td><strong>Study Phase<\/strong><\/td><td>Phase III (pivotal)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>Potential first targeted therapy for thymic carcinoma in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-dual-target-mechanism\">Product Profile &amp; Dual-Target Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target<\/th><th>Biological Function<\/th><th>KC1036 Therapeutic Effect<\/th><\/tr><\/thead><tbody><tr><td><strong>VEGFR2<\/strong><\/td><td>Vascular endothelial growth factor receptor 2; drives tumor angiogenesis<\/td><td><strong>Strong vascular targeting<\/strong> \u2013 suppresses tumor blood supply and growth<\/td><\/tr><tr><td><strong>AXL<\/strong><\/td><td>Receptor tyrosine kinase; promotes tumor immune evasion and metastasis<\/td><td><strong>Enhanced antitumor immunity<\/strong> \u2013 restores host immune response, prevents immune escape<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Mechanistic Synergy:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Anti-Angiogenesis:<\/strong> VEGFR2 inhibition starves tumor of nutrients\/oxygen<\/li>\n\n\n\n<li><strong>Immune Modulation:<\/strong> AXL blockade reverses immunosuppressive tumor microenvironment<\/li>\n\n\n\n<li><strong>Dual-Action Advantage:<\/strong> Simultaneous vascular disruption + immune activation vs. single-target alternatives<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-context-amp-unmet-need\">Disease Context &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Thymic Carcinoma Profile<\/th><\/tr><\/thead><tbody><tr><td><strong>Rarity<\/strong><\/td><td><strong>Ultra-rare malignancy<\/strong>; ~400\u2013500 new cases annually in China<\/td><\/tr><tr><td><strong>Aggressiveness<\/strong><\/td><td>High metastatic potential; poor prognosis with <strong>5-year survival &lt;30%<\/strong> in advanced stages<\/td><\/tr><tr><td><strong>Standard of Care<\/strong><\/td><td>Platinum-based chemotherapy (first-line); <strong>no approved targeted therapies<\/strong> for recurrent\/metastatic disease<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>Desperate need for effective second-line+ treatments; limited clinical trial options<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-development-pathway\">Strategic Context &amp; Development Pathway<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Orphan Drug Potential<\/strong><\/td><td>Eligible for NMPA <strong>breakthrough therapy designation<\/strong> and <strong>orphan drug incentives<\/strong> given ultra-rare indication<\/td><\/tr><tr><td><strong>Global Positioning<\/strong><\/td><td>First-in-class VEGFR2\/AXL inhibitor in thymic carcinoma; potential for <strong>FDA orphan drug designation<\/strong> and <strong>EU PRIME status<\/strong><\/td><\/tr><tr><td><strong>Clinical Strategy<\/strong><\/td><td>Phase III likely <strong>single-arm or small randomized study<\/strong> given rarity; objective response rate (ORR) primary endpoint<\/td><\/tr><tr><td><strong>Revenue Potential<\/strong><\/td><td>Niche market but <strong>premium pricing<\/strong> (~RMB 200,000\u2013300,000 annually per patient); peak sales <strong>RMB 100\u2013150 million<\/strong> in China with potential global licensing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Timeline:<\/strong> Phase III enrollment <strong>Q2 2026<\/strong>; data readout <strong>2028<\/strong>; NDA filing <strong>2029<\/strong> assuming positive efficacy signal<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> No direct competitors; positioned against <strong>investigational immunotherapies<\/strong> (pembrolizumab, nivolumab in small trials) and <strong>chemotherapy rechallenge<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase III execution, clinical efficacy outcomes, and regulatory pathways for KC1036 in thymic carcinoma. Actual results may differ due to patient enrollment challenges in ultra-rare indications, competitive immunotherapy developments, and reimbursement negotiations for orphan oncology therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/603590_20260319_YCSO.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603590_20260319_YCSO.\"><\/object><a id=\"wp-block-file--media-9a7ca598-02db-43a0-a7da-bc0635496e70\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/603590_20260319_YCSO.pdf\">603590_20260319_YCSO<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/603590_20260319_YCSO.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9a7ca598-02db-43a0-a7da-bc0635496e70\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,2984,1532],"class_list":["post-60058","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-konruns-pharmaceutical","tag-sha-603590"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\/AXL Inhibitor Targets Thymic Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate a Phase III clinical study for KC1036, a Category 1 innovative chemical drug. The study targets advanced recurrent or metastatic thymic carcinoma in patients who have failed at least one prior line of platinum-based chemotherapy, positioning KC1036 as a potential first-in-class therapy for this ultra-rare, aggressive malignancy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60058\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\/AXL Inhibitor Targets Thymic Carcinoma\" \/>\n<meta property=\"og:description\" content=\"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate a Phase III clinical study for KC1036, a Category 1 innovative chemical drug. The study targets advanced recurrent or metastatic thymic carcinoma in patients who have failed at least one prior line of platinum-based chemotherapy, positioning KC1036 as a potential first-in-class therapy for this ultra-rare, aggressive malignancy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60058\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-19T15:24:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-19T15:24:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60058#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60058\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\\\/AXL Inhibitor Targets Thymic Carcinoma\",\"datePublished\":\"2026-03-19T15:24:49+00:00\",\"dateModified\":\"2026-03-19T15:24:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60058\"},\"wordCount\":422,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Konruns Pharmaceutical\",\"SHA: 603590\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60058#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60058\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60058\",\"name\":\"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\\\/AXL Inhibitor Targets Thymic Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-19T15:24:49+00:00\",\"dateModified\":\"2026-03-19T15:24:51+00:00\",\"description\":\"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate a Phase III clinical study for KC1036, a Category 1 innovative chemical drug. The study targets advanced recurrent or metastatic thymic carcinoma in patients who have failed at least one prior line of platinum-based chemotherapy, positioning KC1036 as a potential first-in-class therapy for this ultra-rare, aggressive malignancy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60058#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60058\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60058#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\\\/AXL Inhibitor Targets Thymic Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\/AXL Inhibitor Targets Thymic Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate a Phase III clinical study for KC1036, a Category 1 innovative chemical drug. The study targets advanced recurrent or metastatic thymic carcinoma in patients who have failed at least one prior line of platinum-based chemotherapy, positioning KC1036 as a potential first-in-class therapy for this ultra-rare, aggressive malignancy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60058","og_locale":"en_US","og_type":"article","og_title":"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\/AXL Inhibitor Targets Thymic Carcinoma","og_description":"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate a Phase III clinical study for KC1036, a Category 1 innovative chemical drug. The study targets advanced recurrent or metastatic thymic carcinoma in patients who have failed at least one prior line of platinum-based chemotherapy, positioning KC1036 as a potential first-in-class therapy for this ultra-rare, aggressive malignancy.","og_url":"https:\/\/flcube.com\/?p=60058","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-19T15:24:49+00:00","article_modified_time":"2026-03-19T15:24:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60058#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60058"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\/AXL Inhibitor Targets Thymic Carcinoma","datePublished":"2026-03-19T15:24:49+00:00","dateModified":"2026-03-19T15:24:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60058"},"wordCount":422,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Konruns Pharmaceutical","SHA: 603590"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60058#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60058","url":"https:\/\/flcube.com\/?p=60058","name":"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\/AXL Inhibitor Targets Thymic Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-19T15:24:49+00:00","dateModified":"2026-03-19T15:24:51+00:00","description":"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate a Phase III clinical study for KC1036, a Category 1 innovative chemical drug. The study targets advanced recurrent or metastatic thymic carcinoma in patients who have failed at least one prior line of platinum-based chemotherapy, positioning KC1036 as a potential first-in-class therapy for this ultra-rare, aggressive malignancy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60058#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60058"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60058#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Konruns Pharma Wins NMPA Phase III Approval for KC1036 \u2013 Multi-Target VEGFR2\/AXL Inhibitor Targets Thymic Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60058"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60058\/revisions"}],"predecessor-version":[{"id":60061,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60058\/revisions\/60061"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}